GSTM1 and anemia: At the conclusion of the trial, an end assessment survey for NP women showed that anaemia prevalence (Hb < 12 g/dL) was 48.9% in parasitaemic and 39% in non-parasitaemic women, with a prevalence of ID below 20% [15].